The business of generic drug development is often misunderstood as a simple exercise in duplication. For many years, we operated […]

How commercial manufacturing costs actually get built, what drives them, how CDMOs protect their pricing through IP assets, and what

The patent system did not anticipate generative chemistry. When Congress codified the requirement that inventors be ‘natural persons’ in 35

  A deep-dive reference for pharma IP teams, portfolio managers, regulatory strategists, and institutional investors tracking generic market entry timelines.

1. What Are Specialty Generics — and Why the Definition Matters Defining the Asset Class With Precision The term ‘specialty

Key Takeaways (Top-Line Summary) Section I: What Precision Medicine Actually Is — and Why Its IP Complexity Is Unmatched Precision

1. Why Deformulation Is a Patent Strategy Weapon Reverse engineering a branded drug is not simply a chemistry exercise. It

A technical reference for pharma IP counsel, portfolio managers, R&D strategy leads, business development teams, and institutional investors with exposure

What Canada’s Patent Linkage System Actually Does Canada ties the regulatory approval of generic and biosimilar drugs directly to the